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Abstract
Purpose The Drug Burden Index (DBI) is a tool to quantify
the anticholinergic and sedative load of drugs. Establishing
functional correlates of the DBI could optimize drug prescrib-
ing in patients with dementia. In this cross-sectional study, we
determined the relationship between DBI and cognitive and
physical functions in a sample of patients with dementia.
Methods Using performance-based tests, we measured phys-
ical and cognitive functions in 140 nursing home patients aged
over 70 with all-cause dementia. We also determined anticho-
linergic DBI (AChDBI) and sedative DBI (SDBI) separately
and in combination as total drug burden (TDB).
Results Nearly one half of patients (48%) used at least one
DBI-contributing drug. In 33% of the patients, drug burden
Key statements
What is already known about this subject
The Drug Burden Index (DBI) is considered as a broadly applicable tool
to quantify anticholinergic and sedative drug burden. In healthy older
adults, the DBI is associated with physical and cognitive impairments.
In older patients with dementia, this has not yet been investigated.
What this study adds
We found that DBI is unrelated to cognitive and physical functions in a
sample of 140 nursing home patients with dementia. These results may
imply that drug prescribing is more optimal for patients with dementia
compared with healthy older populations.
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was moderate (0 < TDB < 1) whereas in 15%, drug burden
was high (TDB ≥ 1). Multivariate models yielded no associa-
tions between TDB, AChDBI, and SDBI, and physical or
cognitive function (all p > 0.05).
Conclusions A lack of association between drug burden and
physical or cognitive function in this sample of patients with
dementia could imply that drug prescribing is more optimal
for patients with dementia compared with healthy older pop-
ulations. However, such an interpretation of the data warrants
scrutiny as several dementia-related factors may confound the
results of the study.
Keywords DrugBurden Index . Dementia . Inappropriate
prescribing . Nursing home facilities . Medication
Introduction
With the world population progressively growing older, the
number of older adults with dementia increases. Globally,
47.5 million people suffer from dementia, resulting in a health
care expenditure of $600 billion [1]. Cognitive and physical
abilities of patients with dementia decline steadily,
compromising daily function and independence and requiring
approximately one half of patients to move to a nursing home
(NH) and receive assistance [2]. The prevalence of comorbid-
ities among patients with dementia is high [3]. Depending on
the study, 43 to 92% of dementia patients are exposed to
polypharmacy, i.e., the concurrent use of five or more medi-
cations from different drug categories [4–7], which can result
in serious adverse drug reactions (ADRs) such as cognitive
impairment, functional decline, and an increase in risk of falls
and fractures [8, 9]. To minimize suboptimal drug use by older
adults, the Beers criteria categorize inappropriate drugs that
patients should use with caution or avoid [10]. Even though
anticholinergic and sedative psychotropic drugs have espe-
cially high risks to cause adverse effects, it is estimated that
23 to 47% of dementia patients take at least one anticholiner-
gic or sedative drug [11–13].
Several tools exist to quantify anticholinergic drug burden
in older adults, but the agreement between tools is limited
[14]. The Drug Burden Index (DBI) has been identified as
an appropriate tool to quantify anticholinergic and sedative
drug burden in older adults [15–17]. In community-dwelling
older adults, a higher DBI correlates with low physical func-
tion [18–21], high fall rate [22], difficulty in performing ac-
tivities of daily living (ADLs) [20, 21], mortality, and hospi-
talization [23]. However, the evidence is mixed regarding the
relationship between DBI and cognitive function [15, 24, 25].
In dementia patients, a higher DBI correlates with low self-
reported health-related quality of life [7] and a high risk of
hospitalization and mortality [23]. As far as we know, the
relationship between DBI and physical and cognitive
functions has not yet been examined in patients with demen-
tia. To minimize suboptimal drug prescribing for patients with
dementia, it is necessary to establish the functional associa-
tions of the DBI in this patient group.
The purpose of the present cross-sectional study was to
determine the relationship between DBI and cognitive and
physical functions in patients with all-cause dementia. We
quantified the relationship between anticholinergic DBI
(AChDBI), sedative DBI (SDBI), and total drug burden
(TDB = AChDBI + SDBI), and physical and cognitive func-
tions. We hypothesized that AChDBI and SDBI individually
and in combination in the form of TDB are inversely associ-
ated with physical and cognitive functions.
Methods
Design
This study combined data from a Dutch cross-sectional
(Nederlands Trial Register (NTR)1230, 74 participants, data
collected between 2004 and 2007) study and baseline data
from a related Dutch intervention study (NTR2269, 66 partic-
ipants, collected between 2010 and 2014). Each participant or
a legal representative signed an informed consent approved by
the University Medical Ethical Committee. The studies were
conducted in accordance with the principles of the Declaration
of Helsinki (64th amendment).
Sample and procedures
The current sample consisted of 140 NH residents over age 70
with a dementia diagnosis. The two studies differed minimally
in terms of inclusion and exclusion criteria, resulting in the
following overall inclusion criteria for the total sample: age >
70, a physician-diagnosed dementia reported in the medical
chart, the ability to walk short distances without a walking aid,
and an Mini Mental State Examination (MMSE) score ≥ 10
and ≤ 24 (indicating mild to moderate dementia). Multiple
disease-related exclusion criteria were used for safety reasons
(see NTR files 1230 and 2269, Appendix 1). Appendix 1 also
describes the recruitment procedures. Trained research assis-
tants recorded data on sociodemographic factors (age, gender,
level of education) and cognitive and physical abilities. To
minimize test burden, the assessor performed the cognitive
and physical assessments in two separate sessions within
7 days. The researchers extracted data on medical conditions
and medication use for all participants from the nursing
homes’ medical files. Medication data comprised a record of
all medications taken by the participant at the time of assess-
ment and the subsequent dose, frequency, and method of ad-
ministration. We excluded medication as needed, topical
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ointments, lubricating eye drops, and over-the-counter medi-
cations from the current analyses.
Measurements
Medication assessment
To code the drugs, we used the Anatomical Therapeutic
Chemical (ATC) classification system, as recommended by
the World Health Organization [26]. We quantified the total
anticholinergic and sedative load with the DBI and calculated
TDB as follows [15]:
(1) TDB = AChDBI + SDBI
where AChDBI and SDBI represent, respectively, total
anticholinergic and sedative load. We determined sedative
and/or anticholinergic load for each drug and summed up
as follows:
(2) AChDBI or SDBI = Σ Di / (δi + Di)
where Di represents the daily dose taken by the participant
and δ represents the recommended minimum daily dose of
the drugs with an anticholinergic or sedative load, respec-
tively. The recommended minimum daily dose was spec-
ified for each drug (i) based on the lowest minimum oral
dose that is prescribed for any common medical indication
in older adults.
Classification of anticholinergic and sedative drugs
To determine if a drug had sedative and/or anticholinergic
effects, the Expertise Centre Pharmacotherapy in Older
persons (Ephor) [27] was consulted. Figures 1 and 2 show
the decision tree for the classification process. A drug was
classified as anticholinergic when the three most common
anticholinergic side effects (obstipation/constipation,
xerostomia, and urinary retention) were described in
Ephor or in at least two of the remaining sources: the
Summary of Product Characteristics (SmPC [28], the
Pharmacotherapeutic Compass [29], and the Medicines
Information Centre of the Royal Dutch Pharmacists
Association [30]. If all three anticholinergic side effects
were mentioned in one of the remaining sources and at
least one side effect was mentioned in the two other re-
maining sources, the drug was also classified as anticho-
linergic. A drug was classified as sedative when either
sedation, drowsiness, somnolence, or impaired coordina-
tion and reaction time were listed as side effects in Ephor
or at least two of the remaining sources. If a drug was
known to have both anticholinergic and sedative effects,
it was classified as anticholinergic [15].
Polypharmacy
Polypharmacy and excessive polypharmacy were defined as
the concurrent use of five to nine and more than nine drugs,
respectively [4].
Non-DBI-contributing drugs
Other than inclusion in polypharmacy measures, we excluded
all non-DBI-contributing drugs from the current analyses.
Comorbidities
We quantified comorbidity based on the Functional
Comorbidity Index (FCI-18) [31] (Appendix 3). The FCI
comprises 18 medical conditions that negatively impact
physical function. The presence or absence of each condi-
tion is listed. A higher score represents a greater number of
comorbidities.
Functional outcomes
Motor function To characterize motor function, we used sev-
eral performance-based tests that are frequently used for pa-
tients with dementia [32]. Functional mobility was quantified
with the Six Meter Walk Test (meters per second) [33], Timed
Up&Go (seconds) [34], and 30-seconds Sit to Stand (number
of correct attempts) [35]. Balance was measured with the
Frailty and Injuries Cooperative Studies of Intervention
Techniques subtest 4 (FICSIT-4) [36] and Figure of Eight
(seconds) [37]. Grip strength (kg) was assessed using a
Jamar© hand dynamometer.
Cognitive functionWe employed frequently used neuropsy-
chological tests [32] to quantify cognitive function, including
global cognitive function (Mini Mental State Examination)
[38]; verbal memory (Eight Word Task immediate recall and
recognition) [39]; verbal working memory (Digit Span
Forward and Backward) [40]; visual memory (Visual
Memory Span Forward and Backward) [40]; Rivermead
Behavioural Memory Test (RBMT) Faces and Pictures [41];
abstract reasoning (Groninger Intelligence Test (GIT) incom-
plete figures) [42]; and basic information processing speed
(STROOP word card, adapted 45-s version) [43]. We deter-
mined the number of correct responses for all tests as an out-
come measure. For all tasks, higher scores indicate a better
performance.
Statistical analyses
We used SPSS Statistics 23.0 (IBM, Armonk, NY) to compute
means and standard deviations (SDs) for motor and cognitive
outcomes and to analyze the data. Scores on the Six Meter
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Walk Test, Timed Up&Go, and Figure of Eight were positive-
ly skewed and, thus, log10-transformed. We imputed missing
data for cognitive (5.8%missing) and physical (6.0%missing)
variables using the maximum likelihood-expectation maximi-
zation algorithm [44]. The scores on the cognitive and motor
tests as well as sociodemographic factors and comorbidities
were used as predictors for missing data completions.
We set the DBI as a categorical ordinal variable (DBI = 0,
0 < DBI < 1, DBI ≥ 1) [19]. Uncontrolled and controlled
multivariate analyses (MANOVAs) were performed to assess
Fig. 1 Classification process of drug as anticholinergic
Fig. 2 Classification process of drug as sedative
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any differences in functional outcomes between the DBI clas-
ses. The analyses were done separately for the cognitive and
the physical performance scores, as well as for TDB,
AChDBI, and SDBI values.
We identified potential confounders by determining the
correlation between sociodemographic factors, comorbidity
(FCI-18), and cognitive and physical outcomes. Potential con-
founders for cognitive outcomes were age, gender, and edu-
cation. Additionally, FCI-18 was added to the models as a
confounder. Potential confounders for physical outcomes in-
cluded age, gender, education, use of walking aid, and addi-
tionally, FCI-18. We presented the non-transformed data for
transformed variables. We used two-tailed tests, and statistical
significance was set at p < 0.05.
Results
Table 1 shows participants’ characteristics (n = 140, 78.6%
female). The mean age was 85.1 ± 5.7 years. The most fre-
quent dementia diagnoses were Alzheimer’s disease and/or
vascular dementia (92.8% of all cases). The mean MMSE
score was 16.2 ± 4.5, thus being indicative of moderate de-
mentia. Polypharmacy (n = 68, 48.6%) and excessive
polypharmacy (n = 24, 17.1%) were frequent. In total, 105
(75.0%) participants took one or more drugs with anticholin-
ergic (n = 69, 49.3%) or sedative (n = 36, 25.7%) effects. Of
these participants, 46 (32.9%) had a TDB value between 0 and
1 and 21 (15.0%) had a TDB value of ≥ 1. Five participants
used a cholinesterase inhibitor (all rivastigmine). Of these five
participants, only two had a TDB value > 0 (TDB = 0.6 and
TDB = 2.5), thereby limiting the chance of prescribing cas-
cades between anticholinergics and cholinesterase inhibitors
in the current sample. The total number of drugs did not cor-
relate with TDB, AChDBI, or SDBI. Dementia severity as
measured by a MMSE score did not correlate with TDB,
AChDBI, or SDBI (r = − 0.003, r = − 0.002, and r = −
0.002, respectively). Age inversely correlated with TDB
(r = − 0.200, p = 0.018). Table 1 summarizes patient charac-
teristics in the TDB subgroups. Appendix 2 lists the DBI-
contributing drugs used in the sample. The most commonly
used anticholinergic drug was the antidepressant citalopram
(n = 16). Oxazepam, a benzodiazepine, was the most com-
monly used sedative drug (n = 12).
Relationship between DBI and physical function
The model not controlled for confounders revealed no group
differences in measures of motor performance in the TDB
subgroups (F(12,264) = 1.159, p = 0.313, Wilks’ Λ = 0.902,
partial η2 = 0.050). The same applies to physical performance
in AChDBI (F(12,264) = 0.538, p = 0.889, Wilks’ Λ = 0.953,
partial η2 = 0.024) and SDBI (F(12,264) = 1.382, p = 0.174,
Wilks’ Λ = 0.885, partial η2 = 0.059) subgroups. After con-
trolling the models for age, gender, education, and use of
walking aid, there were no differences in physical outcomes
between the subgroups TDB (F(12,220) = 1.063, p = 0.393,
Wilks’ Λ = 0.893, part ial η2 = 0.055), AChDBI
(F(12,220) = 0.766, p = 0.685, Wilks’ Λ = 0.921, partial
η2 = 0.040), or SDBI (F(12,220) = 1.121, p = 0.344, Wilks’
Λ = 0.888, partial η2 = 0.058). When the FCI score is taken
into account as an additional covariate, there were no group
differences for TDB (F(12,206) = 1.114, p = 0.350, Wilks’
Λ = 0.882, partial η2 = 0.061), AChDBI (F(12,206) = 0.726,
p = 0.725, Wilks’ Λ = 0.920, partial η2 = 0.041), and SDBI
(F(12,206) = 1.303, p = 0.219, Wilks’ Λ = 0.864, partial
η2 = 0.071).
Relationship between DBI and cognitive function
In the multivariate model not controlled for potential con-
founders, cognitive outcomes were not different for the TDB
classes (F(22,254) = 1.191, p = 0.256, Wilks’ Λ = 0.822, par-
tial η2 = 0.093). We found equivocal results when the
AChDBI (F(22,254) = 0.976, p = 0.495, Wilks’ Λ = 0.850,
partial η2 = 0.078) or the SDBI (F(22,254) = 1.005, p = 0.459,
Wilks’ Λ = 0.846, partial η2 = 0.080) were taken into account
separately. After controlling for age, gender, and education,
there were no differences in cognitive outcomes between the
subgroups TDB (F(22,220) = 1.303, p = 0.171, Wilks’
Λ = 0.783, partial η2 = 0.115), AChDBI (F(22,220) = 1.074,
p = 0.377, Wilks’ Λ = 0.815, partial η2 = 0.097), and SDBI
(F(22,220) = 1.170, p = 0.277, Wilks’ Λ = 0.801, partial
η2 = 0.105). With FCI as an additional covariate, there were
no differences in cognitive outcomes between the TDB
(F(22,206) = 1.352, p = 0.142, Wilks’ Λ = 0.764, partial
η2 = 0.126), AChDBI (F(22,206) = 1.052, p = 0.403, Wilks’
Λ = 0.808, partial η2 = 0.101), and SDBI (F(22,206) = 1.250,
p = 0.210, Wilks’ Λ = 0.778, partial η2 = 0.118) subgroups.
Discussion
To our best knowledge, this is the first cross-sectional study to
examine functional correlates of the DBI in a population of
patients with mild-to-moderate all-cause dementia. We used a
wide range of reliable and valid measurements to assess cog-
nitive and physical functions. We found no multivariate rela-
tionships between DBI and cognitive and physical functions.
Relationship between drug burden and physical function
In the present study, TDB did not correlate with physical
function. We hypothesized that TDB would negatively corre-
late with physical function because anticholinergic and seda-
tive drugs target central nervous system (CNS) functions that
Eur J Clin Pharmacol (2017) 73:1633–1642 1637
affect physical function, such as the gastrointestinal system
and neuromuscular processes [21]. A lack of association be-
tween TDB and physical function in our study contrasts with
data in cognitively healthy populations [18–20], possibly for
two dementia-related potential reasons.
First, drug prescribing might be more optimal for patients
with dementia compared with healthy older populations. For
dementia patients, a larger emphasis may be placed upon tol-
erability and quality of life instead of treatment of symptoms
and quantity of life, resulting in better-tailored drug prescrib-
ing [45]. Indeed, in our sample, less than half of patients used
DBI drugs, which is a lower rate compared with the rate in a
sample of healthier older adults [46]. Such a careful approach
may become even more pronounced with older age, a hypoth-
esis perhaps reflected by a negative relationship between age
and TDB in our study. Not only the presence but also the
severity of dementia may be related to more appropriate pre-
scribing. However, dementia severity (as measured with
MMSE) and DBI were unrelated in our study, confirming a
lack of covariation between the odds of being prescribed
inappropriate medication and dementia severity [6]. Thus,
the presence rather than severity of dementia may be a better
indicator of lower risk of suboptimal prescribing.
A second reason why our results showed no relationship
between physical function and drug burden could be that nu-
merous dementia-related factors that affect physical health
might confound the relationship between TDB and physical
function in patients with dementia. Dementia progression
[47], age, poor health [48], sedentariness [49], adverse life
events, and a decline in general well-being [50] all unfavor-
ably affect physical function. The presence and manifestation
of such factors may greatly vary in patients with dementia and
thus increase variability within the sample. In combination,
these factors might minimize the influence of DBI drugs on
physical and cognitive function, nullifying a potential relation.
However, this hypothesis of confounding factors is weakened
by the results of a previous randomized controlled trial (RCT)
that aimed to reduce anticholinergic exposure through a 12-
week reduction intervention in institutionalized patients with
dementia. The authors found that physical function as
Table 1 Patient characteristics in the total sample (N = 140)
Characteristics Valuea TDB = 0 0 < TDB < 1 TDB ≥ 1
N (% of total) 140 (100) 73 (52.1) 46 (32.9) 21 (15.0)
Age (years; mean, SD) 85.13 (5.69) 85.92 (5.71) 84.85 (5.38) 83.00 (5.90)
Gender (N women, % of total) 110 (78.6) 58 (79.5) 35 (76.1) 17 (81.0)
Education (N, % of total)
1 = primary education only 29 (23.6) 14 (21.2) 12 (30.8) 3 (16.7)
2 = secondary lower education 77 (62.6) 42 (63.6) 22 (56.4) 13 (72.2)
3 = secondary higher education 17 (13.8) 10 (15.2) 5 (12.8) 2 (11.1)
Use of walking aid (N, % of total)
No 64 (45.7) 35 (47.9) 22 (47.8) 10 (47.6)
Yes 70 (50.0) 38 (52.1) 24 (52.2) 11 (52.4)
Dementia diagnosis according to medical file (N, % of total)
1 = Alzheimer’s disease (AD) 86 (61.4) 49 (67.1) 26 (56.6) 13 (61.9)
2 = vascular dementia (VD) 16 (11.4) 6 (8.2) 10 (21.8) 3 (14.3)
3 = mixed (AD + VD) 28 (20.0) 16 (21.9) 10 (21.7) 2 (9.5)
4 = dementia with Lewy bodies (DLB) 5 (3.6) 2 (2.7) 0 (0.0) 3 (14.3)
MMSE, mean (SD) 16.16 (4.5) 16.49 (0.53) 15.44 (0.66) 16.57 (0.98)
Total Drug Burden Index 0.43 (0.58) 0.00 (0.00) 0.61 (0.18) 1.55 (0.44)
Anticholinergic Drug Burden Index 0.27 (0.43) 0.00 (0.00) 0.40 (0.28) 0.92 (0.58)
Sedative Drug Burden Index 0.16 (0.33) 0.00 (0.00) 0.21 (0.30) 0.63 (0.46)
Total number of medications used (mean, SD) 5.71 (3.07) 5.64 (3.03) 5.67 (2.94) 6.05 (3.54)
Polypharmacy (N, % of total)
No 48 (34.3) 36 (49.3) 11 (23.9) 1 (4.8)
Polypharmacy (5–9) 68 (48.6) 28 (38.4) 26 (56.5) 14 (66.7)
Excessive polypharmacy (> 9) 24 (17.1) 9 (12.3) 9 (19.6) 6 (28.6)
Functional Comorbidity Index total (mean, SD) 1.88 (1.52) 1.65 (1.36) 2.14 (1.52) 2.15 (1.69)
TDB total Drug Burden Index
aData were missing for level of education (n = 17), use of walking aid (n = 6), dementia diagnosis (n = 5), and Functional Comorbidity Index total
(n = 11)
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measured with the Barthel Index did not improve after a de-
crease in anticholinergic exposure after 12 weeks [51].
Considering that the randomized controlled nature of the
study should minimize the influence of confounding vari-
ables, we cannot definitively conclude that confounding fac-
tors underlie the lack of relationship between drug burden and
physical function.
Our findings qualitatively agree with data in hospitalized
patients with multimorbidity, 43.5% of whom suffered from
dementia. In these patients, the use of three or more psycho-
tropic drugs was related to lower hand-grip strength in both
hands, but not lower extremity muscle strength [52].
However, further comparisons of our sample with other de-
mentia populations are difficult because the relationship be-
tween drug burden (DBI or other measures) and physical
function in patients with dementia is understudied. Future re-
search should improve our understanding of the relationship
between physical function and drug burden in this patient
group. Within such research, it is important to consider the
care setting as being a determinant for more appropriate pre-
scribing in patients with dementia. Our sample included pa-
tients with dementia in nursing homes, who may be at a lower
risk of suboptimal prescribing compared with community-
dwelling populations with or without cognitive impairment
[23, 46]. Indeed, the use of DBI drugs declines by approxi-
mately 5% after NH admission [53, 54], although there is a
paucity of data concerning DBI drug usage in specifically
Dutch NHs. There may be four reasons why DBI drug pre-
scribing may be more optimal after NH admission: (1) NH
physicians may be less inclined to prescribe DBI drugs be-
cause they are specialized in the medical aspects of older pa-
tients compared with primary care physicians [54]; (2) NH
staff can quickly recognize and address the adverse effects
of DBI-contributing drugs; (3) behavioral disturbances are
generally less medicalized in a NH versus home setting be-
cause behavior is interpreted in a broader, more accepting
context and approached as such [55]; and (4) NH physicians,
in particular, might recognize the diminished benefit of drugs
in light of patients’ low functional level [56, 57]. However, the
present study could not examine in more detail the impact of
care setting on drug burden, as we studied only a NH
population.
In addition to TDB, we hypothesized that higher AChDBI
and SDBI separately correlated with lower physical function.
Separate associations of AChDBI versus SDBI with physical
function could arise from pharmacodynamic differences be-
tween these two drug classes: whereas anticholinergic drugs
mainly target the cholinergic system involved in excitatory
processes, sedative drugs generally influence inhibitorymech-
anisms by targeting levels of gamma-aminobutyric acid
(GABA), although several DBI drugs target both systems
(e.g., citalopram). In older women, anticholinergic compared
with sedative drug burden (not measured with DBI) more
strongly correlated with impaired balance, mobility, gait, chair
stands, and grip strength [58]. Sedative burden was associated
with impaired mobility and grip strength only. In contrast,
Gnjidic et al. [21] reported that SDBI predicted poorer perfor-
mance on measures of gait, balance, and grip strength in older
men, whereas AChDBI was associated with weaker grip
strength only. The difference between these studies might be
explained by differences in sedative drug usage [58] or gender
differences. However, contrasting with these studies, neither
AChDBI nor SDBI correlated with physical function in our
sample. The effects of anticholinergic and sedative drugs may
be less discernible in dementia patients versus community-
dwelling populations because amyloid β deposition in
Alzheimer’s disease (AD) disrupts the excitatory/inhibitory
balance system [59]. Consequently, DBI drugs that target the
anticholinergic system may disrupt the GABA system as well
(and vice versa). Thus, functional correlates of AChDBI/
SDBI, if any, may be indiscernible in dementia patients.
Relationship between drug burden and cognitive function
Contrary to our hypothesis, we found no association between
TDB and cognitive function. Associations between higher
drug burden and lower cognitive function in other populations
can be explained by the detrimental effects of anticholinergic
and sedative drugs on CNS processes involving vision, atten-
tion, sedation, and psychomotor speed [21]. The finding that
higher anticholinergic burden was not related to lower cogni-
tive function is similar to the results of a study in 224
community-dwelling patients with AD, where anticholinergic
load was quantified with the Anticholinergic Burden scale
[60], and in line with a study in patients with multimorbidity
(43.5% dementia) showing that users of anticholinergic or
sedative drugs did not have lower cognitive function com-
pared with non-users [52]. The aforementioned explanations
for a lack of association between TDB and physical function
may be equally applicable to the lack of association between
TDB and cognitive function. That is, drug prescribing may be
more optimal for patients with dementia compared with
healthy older populations because of a higher emphasis on
tolerability and quality of life instead of treatment of symp-
toms and quantity of life. Alternatively, the effects of drug use
on cognitive function may be harder to detect in patients with
dementia due to the large variety of dementia-related influenc-
ing factors.
Similar to TDB, we found no evidence in support of our
hypothesis that higher AChDBI and SDBI are separately as-
sociated with lower cognitive function. In older women,
higher anticholinergic burden (not measured with DBI) corre-
lated more strongly with lower global cognitive function than
sedative burden [58]. No evidence was reported for different
cognitive domains. In addition, a higher AChDBI was associ-
ated with lower memory performance and lower performance
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on the Trail Making Test B in cognitively healthy older adults
[25]. No associations between SDBI and cognitive domains
were reported. The lack of discernible associations of anticho-
linergic versus sedative drugs on cognitive function in our
study may result from the simultaneous dysregulation of the
excitatory/inhibitory systems by either anticholinergic or sed-
ative drugs in patients with dementia, as described previously
in this paper.
Study limitations
Several limitations warrant caution in interpreting our results.
First, the sample size of the current study is small compared to
other studies [18] and the studied DBI subgroups were of
unequal sizes. This might have negatively affected statistical
power. Second, our sample consisted of patients with mild to
moderate dementia, with the mean MMSE score indicating
moderate dementia. Therefore, the results are not directly gen-
eralizable to a more severe dementia population. Also, due to
the cross-sectional design of our study, we cannot exclude the
issue of confounding by indication. We are thus unable to
make claims about causal effects of DBI drugs on functional
outcomes in dementia. A complicating factor is that the effi-
cacy of DBI drugs in the later stages of dementia is not yet
adequately assessed. To gain an optimal understanding of the
positive and negative effects of DBI drugs in dementia pa-
tients, future experimental studies on the efficacy of DBI
drugs with varying degrees of dementia are needed.
Additionally, differences between how previous studies and
we classified DBI is one source of inconsistency [18]. The
source of this inconsistency is a lack of consensus as to which
drugs to classify as anticholinergic, sedative, or both. In par-
ticular, the current DBI may be an underestimation of the true
anticholinergic and sedative burden, as drugs with both anti-
cholinergic and sedative effects are classified as anticholiner-
gic only. Thus, our indices, compared with other studies,
could yield a different drug burden value compared with other
methods. To minimize such differences, we used a detailed
classification process that included several reliable sources
and we also strictly adhered to the original method [15] in
estimating DBI. Also, the DBI does not account for medica-
tions as needed, which could have influenced the study results
if participants took such medications before the assessments.
Furthermore, patients with dementia in NHs may be inherent-
ly different from community-dwelling patients. Associations
of DBI with functional outcomes are therefore not directly
generalizable to a community-dwelling dementia population.
Further research could focus on the associations of DBI with
functional outcomes in different samples of community-
dwelling versus institutionalized patients with dementia.
Longitudinal research could be done by following dementia
patients through the process of institutionalization, while
tracking medication records and functional outcomes. In
addition, the mean number of comorbidities in our sample
(M = 2) was lower compared with that in another sample of
NH patients with dementia (M = 4, on a summary scale (not
FCI)) [61]. The difference between our study and the study by
Sloane et al. [61] could result from the exclusion of people
with multiple health-related conditions in our sample, which
could have resulted in a healthier-than-average group of par-
ticipants. Contrarily, the FCI does not comprise all medical
conditions, and the lower comorbidity scores in our sample
may have resulted from the exclusion of several medical con-
ditions on the FCI, such as cancer or thyroid disease.
Altogether, caution is advised when generalizing our results
to other NH patients with dementia. Moreover, the DBI does
not include a weighting factor for the relative anticholinergic
activity of each DBI drug. Not all drugs have equally strong
anticholinergic effects [62]. The use of specifically high po-
tency anticholinergics has been linked to an increased risk of
all-cause dementia in older adults [63]. Duran et al. [64] pro-
vide a differentiation in anticholinergic potency of drugs with
anticholinergic properties (Appendix 2). Appendix 2 shows
that our sample predominantly used drugs with low anticho-
linergic potency, which is not reflected in the DBI. This may at
least partly account for the absence of a relationship between
DBI and functional outcomes and warrants a careful general-
ization of our results to other NH populations with dementia.
Lastly, Dutch NHs might be inherently different in terms of
drug-prescribing practices compared with NHs in other coun-
tries [65]. Therefore, we urge caution in generalization of
these results to other NHs.
Clinical implications
A lack of association between DBI and functional outcomes
raises questions about the DBI as a clinical assessment tool of
drug burden in patients with dementia. DBI is considered as a
valid and useful tool to evaluate drug burden in many popu-
lations. However, it does not account for the many drug-drug
interactions between DBI drugs. Also, the DBI does not con-
sider possible adverse effects of other non-DBI-contributing
drugs. The identification of inappropriate prescribing in pa-
tients with dementia is particularly challenging because
evidence-based guidelines are lacking and health care practi-
tioners are unsure about the best prescribing choices [66]. As a
result, DBI might over- or underestimate true drug burden. To
prevent underestimation of drug burden, perceivedmedication
effects could be assessed by inquiring patients and caregivers.
Conclusion
In contrast with previous studies in healthy older adults, DBI
did not correlate with cognitive and physical functions in a
sample of institutionalized patients with dementia. The lower
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use of DBI contributing drugs in our sample compared with a
community-dwelling healthy population might indicate that
drug prescribing is more optimal for patients with dementia
compared with cognitively healthy older adults. Further ex-
perimental research into the efficacy of DBI drugs for patients
with dementia of different severities and etiologies, and in
different care settings, is needed to clarify the relationship
betweenDBI and functional outcomes in patients with demen-
tia. To achieve or maintain optimal disease management for
patients with dementia, prudence is urged when prescribing
anticholinergic or sedative drugs for the treatment of neuro-
psychiatric complaints.
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